Osiris's stem cells fail two phase III trials in GvHD
This article was originally published in Scrip
Executive Summary
Osiris Therapeutics's stem cell treatment Prochymal has failed to improve complete response rates in two late-stage trials for graft versus host disease (GvHD) – one in newly-diagnosed GvHD and the other in steroid-refractory GvHD. While Osiris emphasised its product's success in treating a subset of patients suffering from liver GvHD, the company's share price fell by 34% to close at $8.03 on September 8th on Nasdaq.